Treatment of Pulmonary Hemangiomatosis with Recombinant Interferon Alfa-2a

New England Journal of Medicine

Volumn 320, Issue 18, 1989, Pages 1197-1200

  White, Carl W ^a   Sondheimer, Henry M ^a   Crouch, Edmond C ^b   Wilson, Harry ^a   Fan, Leland L ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b BARNES JEWISH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; RECOMBINANT ALPHA2A INTERFERON;

CASE REPORT; CHILD; HEMANGIOMATOSIS; HUMAN; LUNG ANGIOGRAPHY; LUNG DISEASE; MALE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0024517730     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198905043201807     Document Type: Article

References (28)

1. Magee F, Wright JL, Kay JM, Peretz D, Donevan R, Churg A. Pulmonary capillary hemangiomatosis. Am Rev Respir Dis 1985; 132: 922–5.
2. Tron V, Magee F, Wright JL, Colby T, Churg A. Pulmonary capillary hemangiomatosis. Hum Pathol 1986; 17: 1144–50.
3. Whittaker JS, Pickering CA, Heath D, Smith P. Pulmonary capillary haemangiomatosis. Diagn Histopathol 1983; 6: 77–84.
4. Wagenvoort CA, Beetstra A, Spijker J. Capillary haemangiomatosis of the lungs. Histopathology 1978; 2: 401–6.
5. Rowen M, Thompson JR, Williamson RA, Wood BJ. Diffuse pulmonary hemangiomatosis. Radiology 1978; 127: 445–51.
6. Vevaina JR, Mark EJ. Thoracic hemangiomatosis masquerading as interstitial lung disease. Chest 1988; 93: 657–9.
7. Daroca PJ Jr, Mansfield RE, Ichinose H. Pulmonary veno-occlusive disease: report of a case with pseudoangiomatous features. Am J Surg Pathol 1977; 1: 349–55.
8. Langleben D, Heneghan JM, Batten AP, et al. Familial pulmonary capillary hemangiomatosis resulting in primary pulmonary hypertension. Ann Intern Med 1988; 109: 106–9.
9. Weir EK, Reeves JT, eds. Pulmonary hypertension. Mount Kisco, N.Y.: Futura, 1984.
10. Jaffé RH. Multiple hemangiomas of the skin and of the internal organs. Arch Pathol 1929; 7: 44–54.
11. Holden KR, Alexander F. Diffuse neonatal hemangiomatosis. Pediatrics 1970; 46: 411–21.
12. Koblenzer PJ, Bukowski MJ. Angiomatosis (hamartomatous hem-lymphangiomatosis): report of a case with diffuse involvement. Pediatrics 1961; 28: 65–76.
13. Brouty-Boye D, Zetter BR. Inhibition of cell motility by interferon. Science 1980, 208: 516–8.
14. Friesel R, Komoriya A, Maciag T. Inhibition of endothelial cell proliferation by gamma-interferon. J Cell Biol 1987; 104: 689–96.
15. Heyns AD, Eldor A, Vlodavsky I, Kaiser N, Fridman R, Panet A. The antiproliferative effect of interferon and the mitogenic activity of growth factors are independent cell cycle events: studies with vascular smooth muscle cells and endothelial cells. Exp Cell Res 1985; 161: 297–306.
16. Vilček J. Gresser I, Merigan TC, eds. Regulatory functions of interferons. Ann NY Acad Sci 1980; 350: 1–641.
17. Pfeffer LM, Wang E, Tamm I. Interferon effects on microfilament organization, cellular fibronectin distribution, and cell motility in human fibroblasts. J Cell Biol 1980; 85: 9–17.
18. Feldman D, Goldstein AL, Cox DC, Grimley PM. Cultured human endothelial cells treated with recombinant leukocyte A interferon: tubuloreticular inclusion formation, antiproliferative effect, and 2',5' oligoadenylate synthetase induction. Lab Invest 1988; 58: 584–9.
19. Grimley PM, Davis GL, Kang Y-H, Dooley JS, Strohmaier J, Hoofnagle JH. Tubuloreticular inclusions in peripheral blood mononuclear cells related to systemic therapy with α-interferon. Lab Invest 1985; 52: 638–49.
20. Granstein RD, Murphy GF, Margolis RJ, Byrne MH, Amento EP. Gamma-interferon inhibits collagen synthesis in vivo in the mouse. J Clin Invest 1987; 79: 1254–8.
21. Eldor A. Fridman R, Vlodavsky I, Hy-Am E, Fuks Z, Panet A. Interferon enhances prostacyclin production by cultured vascular endothelial cells. J Clin Invest 1984; 73: 251–7.
22. Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol 1986: 4: 234–43.
23. Groopman JE, Gottlieb MS, Goodman J, et al. Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med 1984; 100: 671–6.
24. Real FX, Oettgen HF, Krown SE. Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon. J Clin Oncol 1986; 4: 544–51.
25. Rios A, Mansell PW, Newell GR, Reuben JM, Hersh EM, Gutterman JU. Treatment of acquired immunodeficiency syndrome–related Kaposi's sarcoma with lymphoblastoid interferon. J Clin Oncol 1985; 3: 506–12.
26. Merigan TC. Human interferon as a therapeutic agent: a decade passes. N Engl J Med 1988; 318: 1458–60.
27. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235: 442–7.
28. Ingber D, Folkman J. Inhibition of angiogenesis through modulation of collagen metabolism. Lab Invest 1988; 59: 44–51.